Markers of bone turnover and disease status in prostate cancer

Markers of bone turnover and disease status in prostate cancer

Bibliographic Details
Main Authors:	Hannon, R, Wells, J, Hamdy, F, Hoyle, N, Eastell, R
Format:	Conference item
Published:	2003

Similar Items

Imaging the effects of castration on bone turnover and hormone-independent prostate cancer colonization of bone.
by: Cross, N, et al.
Published: (2008)

The value of bone turnover markers in the prediction of vertebral fracture in patients using oral glucocorticoids.
by: van Staal, T, et al.
Published: (2003)

The value of bone turnover markers in the prediction of vertebral fracture in patients using oral glucocorticoids.
by: van Staa, T, et al.
Published: (2003)

Effectiveness and cost-effectiveness of prognostic markers in prostate cancer.
by: Calvert, N, et al.
Published: (2003)

Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide
by: Blumsohn, A, et al.
Published: (2011)

Prognostic value of serum markers for prostate cancer.
by: Stenman, U, et al.
Published: (2005)

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
by: Eaton, C, et al.
Published: (2004)

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.
by: Vasikaran, S, et al.
Published: (2011)

The role of the microenvironment in prostate cancer-associated bone disease
by: Edwards, C, et al.
Published: (2016)

Biochemical markers of bone turnover and bone loss at the lumbar spine and femoral neck: the Taiji study.
by: Yoshimura, N, et al.
Published: (1999)

A meta-analysis of reference markers of bone turnover for prediction of fracture.
by: Johansson, H, et al.
Published: (2014)

A new in vivo model of prostate cancer metastasis to bone
by: Reeves, K, et al.
Published: (2010)

The homing of prostate cancer to bone in vivo is modulated by Zoledronic acid
by: Reeves, K, et al.
Published: (2011)

A meta-analysis of reference markers of bone turnover for prediction of fracture
by: Johansson, H, et al.
Published: (2014)

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.
by: Vasikaran, S, et al.
Published: (2011)

Bisphosphonates prevent bone loss early after renal transplantation with concomitant fall in bone turnover markers
by: Hofker, H, et al.
Published: (2007)

Letter to the editor: re: Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women?
by: Reeve, J
Published: (2016)

Bone turnover markers: Do they explain risk associated with previous fracture? The epos study
by: Vergnaud, P, et al.
Published: (2000)

Bone turnover markers: Do they explain risk associated with previous fracture? The EPOS study
by: Vergnaud, P, et al.
Published: (2000)

Screening for prostate cancer: an update.
by: Bryant, R, et al.
Published: (2008)

S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors.
by: Rehman, I, et al.
Published: (2004)

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
by: Generali, D, et al.
Published: (2008)

Study on vitamin D status and determination of optimum vitamin D level based on bone turnover markers in Kota Bharu, Kelantan
by: Muda, Noor Bayani Che
Published: (2017)

Tumor markers in prostate cancer I: blood-based markers.
by: Shariat, S, et al.
Published: (2011)

Staging in prostate cancer.
by: Wilkinson, B, et al.
Published: (2002)

Biochemical Markers of Bone Resorption Compared with Estimates of Bone Resorption from Radiotracer Kinetic Studies in Osteoporosis
by: Eastell, R, et al.
Published: (1997)

Novel biomarkers for the detection of prostate cancer
by: Jakobsen, N, et al.
Published: (2017)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
by: Eaton, C, et al.
Published: (2004)

The role of osteoprotegerin in breast and prostate cancer
by: Holen, I, et al.
Published: (2002)

Management of low-risk prostate cancer.
by: Gardiner, R, et al.
Published: (2008)

Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
by: Bradbury, L, et al.
Published: (2012)

Prostate cancer: screening approaches.
by: Donovan, J, et al.
Published: (2005)

Prostate cancer: screening approaches
by: Donovan, J, et al.
Published: (2005)

Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
by: Nyambo, R, et al.
Published: (2004)

Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A.
by: Leiblich, A, et al.
Published: (2007)

Screening for prostate cancer remains controversial.
by: Neal, D, et al.
Published: (2009)

Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project
by: van Gils, M, et al.
Published: (2005)

Can androgen receptor levels in the prostate predict non-organ-confined prostate cancer?
by: Hamdy, F
Published: (2005)

An estimate of the turnover rate of bone-derived plasma alkaline phosphatase in Paget's disease.
by: Walton, R, et al.
Published: (1975)

Laboratory markers predict bone loss in Crohn's disease: Relation to PBMC function and nutritional status
by: Trebble, T, et al.
Published: (2004)